Is rifampin a safe and effective treatment for pruritus caused by chronic cholestasis?

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 4, 2007, Pages 200-201

  Heathcote, E Jenny ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; PHENOBARBITAL; PLACEBO; RIFAMPICIN;

ANOREXIA; BLOATING; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DEFECATION HABIT; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; KIDNEY FAILURE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; SHORT SURVEY; SIDE EFFECT; TASTE AVERSION; TOXIC HEPATITIS; TREATMENT RESPONSE;

EID: 34247241681     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0746     Document Type: Short Survey

References (5)

1. McElroy PD et al. (2005) National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 41: 1125-1133
2. Gorski JC et al. (2003) The effects of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74: 275-287
3. Prince MI et al. (2002) Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50: 436-439
4. Muthukumar T et al. (2002) Acute renal failure due to rifampin: A study of 25 patients. Am J Kidney Dis 40: 690-696
5. Khokhar O et al. (2005) Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: An unusual reaction. Dig Dis Sci 50: 207-221